Thermo Fisher (TMO) Unveils New Line of Low-Flow HPLC Columns
Thermo Fisher Scientific, Inc. TMO recently introduced µPAC Neo HPLC Columns for proteomics and biopharmaceutical research laboratories. The addition of a new line of low-flow HPLC columns will improve the separation performance and stability of biologically complex samples.
More on µPAC Neo HPLC Columns
Thermo Fisher’s µPAC Neo HPLC has Unique column technology that delivers optimal sample coverage and improved protein identification. Its extra-high resolution separates the most complex samples.
Moreover, its excellent column reproducibility offers more reliable data interpretation. It has long column lifetimes, reducing the number of column exchanges and increasing system uptime.
Benefits of µPAC Neo HPLC Columns
Thermo Scientific µPAC Neo HPLC’s leverages a unique micro-pillar separation structure, which enables researchers to examine proteomics samples in more detail, from accurate identification of peptides to determination of protein quantities, discovery of disease biomarkers and post-translational modifications.
The latest addition to the portfolio is preferably appropriate for the smallest sample sizes in single-cell proteomics separations and features built-in nanoViper connections to the Vanquish Neo UHPLC systems for convenient use and minimized risk of errors.
Image Source: Zacks Investment Research
µPAC Neo columns are manufactured by micromachined etching of silicon wafers, resulting in highly reproducible separation paths. For proteomics researchers, this offers higher column-to-column consistency and longer column lifetimes than packed-bed columns, enabling more robust development and validation of methods and easier study of larger sample batches.
Industry Prospects
Per a report by Grand View Research, the global proteomics market size was valued at $22.30 billion in 2021 and is expected to expand at a CAGR of 13.5% by 2030. Growing demand for personalized medicines & advanced diagnostics in targeted disease treatment and the high prevalence of target diseases are the factors fuelling the market.
Recent Developments
In February 2023, Thermo Fisher announced the launch of its Applied Biosystems TrueMark STI Select Panel — a polymerase chain reaction (PCR) research use-only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium in one test and RNase P, included as a human internal control.
In the same month, Thermo Fisher launched two water analysis systems for environmental, agricultural and industrial testing. Through custom-designed software, the new Thermo Scientific Gallery Aqua Master and Thermo Scientific Gallery Plus Aqua Master analyzers deliver extensive workflow automation for high-throughput, simultaneous multiparameter wet chemistry testing following EPA-approved methods and international standards.
Price Performance
Shares of the company have gained 3% in the past year against the industry’s fall of 12%.
Zacks Rank and Key Picks
Currently, Thermo Fisher carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the overall healthcare sector include Haemonetics Corporation HAE, TerrAscend Corp. TRSSF and Akerna Corp. KERN . Haemonetics and TerrAscend both sport a Zacks Rank #1, while Akerna carries a Zack Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has risen 42.1% in the past year. Earnings Estimates for Haemonetics have increased from $2.87 per share to 2.91 for 2023 and from $3.02 per share to $3.28 for 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the last four quarters, delivering an average surprise of 10.98%. In the last reported quarter, it reported an earnings surprise of 7.59%.
Estimates for TerrAscend in 2023 have remained constant at a loss of 10 cents per share in the past 30 days. Shares of TerrAscend have declined 70.6% in the past year.
TerrAscend’s earnings beat estimates in one of the last three quarters and missed the mark in the other two, the average negative surprise being 136.11%. In the last reported quarter, TRSSF delivered an earnings surprise of 216.67%.
Akerna’s stock declined 95.7% in the past year. Its estimates for 2023 have remained constant at a loss of $1.91 per share over the past 30 days.
Akerna missed earnings estimates in each of the last four quarters, delivering a negative earnings surprise of 15.49% on average. In the last reported quarter, KERN delivered a negative earnings surprise of 13.33%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Akerna Corp. (KERN) : Free Stock Analysis Report
TerrAscend Corp. (TRSSF) : Free Stock Analysis Report
